通过FDA批准的RdRp抑制剂抑制HEV复制
Preeti Hooda1, Mohammed Al-Dosari2, Neha Sinha3
1Virology Lab, Department of Life Sciences, Shiv Nadar Institute of Eminence, Gautam Budh Nagar 201314, India.
ACS omega
|November 16, 2023
概括
费维皮拉维尔和索福斯布维尔在治疗E型肝炎病毒 (HEV) 感染方面表现有前途,通过抑制病毒RNA依赖RNA聚合酶. 组合疗法显著减少了病毒RNA,这表明法维皮拉维尔是一种潜在的抗HEV药物.
科学领域:
- 病毒学 病毒学
- 肝病学 肝病学是一种肝病学.
- 药物发现 药物发现 药物发现
背景情况:
- 肝炎E病毒 (HEV) 引起急性和慢性肝炎,慢性病例的治疗选择有限.
- 目前慢性HEV的治疗方法包括基化干扰素α和利巴维林.
- 病毒RNA依赖RNA聚合酶 (RdRp) 对于HEV复制和潜在的抗病毒标至关重要.
研究的目的:
- 选已知RNA-依赖RNA聚合酶 (RdRp) 抑制分子的抗HEV活性.
- 评估法维皮拉维尔和索福斯布维尔作为单疗法和联合治疗对HEV的疗效.
- 确定用于治疗乙型肝炎的有前途的抗病毒药物.
主要方法:
- 对RdRp抑制剂的查:法维皮拉维尔,索福斯布维尔,雷德西维尔,菲利布维尔和特戈布维尔.
- 对所选化合物的RdRp抑制活性 (IC50值) 的体外评估.
- 通过测量病毒RNA拷贝数来评估组合疗法的疗效.
主要成果:
- 费维皮拉维尔和索福斯布维尔显著抑制了HEV RdRp活性,IC50值分别为10.2 ± 4.9 μM和5.2 ± 2.9 μM.
- 利巴维林作为参考药物,其IC50为3.5±1.6μM.
- 与法维皮拉维尔和索福斯布维尔的联合治疗使病毒RNA拷贝数量减少了约90%,表明了附加效应.
结论:
- 费维皮拉维尔和索福斯布维尔是HEV RdRp的有效抑制剂.
- 费维皮拉维尔和索福斯布维尔的联合治疗显示出治疗肝炎E的显著潜力.
- 费维皮拉维尔是作为抗HEV治疗剂进一步开发的有希望的候选药物,特别是在组合疗法中.
相关概念视频
Viruses with RNA Genomes
34
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
34
Retrovirus Life Cycles
46.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.0K


